Lotus Pharmaceuticals (路坦制药有限公司) announced that its Q3 net income climbed 45% to $3.2 million, even though revenues dropped slightly in the quarter to $16.6 million. The company earned 7 cents per share, fully diluted, bringing its nine-month eps total to 16 cents. Lotus reported that its revenue mix, when compared to the year-ago quarter, were the reason that earnings increased while revenue stayed flat. More details...

Stock Symbol: (OTCBB: LTUS)